AAISG 2026 Annual Meeting

Stone Mountain, GA US
May 1, 2026 to May 3, 2026

The 2026 AAISG Annual Meeting is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology and the Allergy, Asthma & Immunology Society of Georgia.  
This year's annual meeting is an eight-hour event with Faculty who are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Society of Georgia (AAISG).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commercial support was received for this activity.

Target Audience

Practicing allergists
Primary care physicians

Learning Objectives

At the conclusion of this activity, learners should be able to…
1. Apply updated anaphylaxis practice parameter recommendations to recognize, treat, and coordinate follow up care for patients experiencing anaphylaxis, including those using novel epinephrine delivery systems.
2. Compare the indications, advantages, and limitations of available and emerging epinephrine delivery devices in order to select the most appropriate option for individual patients and settings.
3. Analyze clinical “red flag” features and laboratory data to identify patients who warrant evaluation for inborn errors of immunity and referral for specialized testing.
4. Integrate current practice parameter recommendations and genetic testing strategies to develop evidence based diagnostic and management plans for patients with suspected or confirmed inborn errors of immunity.
5. Evaluate system level, ethical, and access barriers to genetic and advanced therapies for inborn errors of immunity and formulate advocacy or practice level strategies to improve timely diagnosis and equitable care.
 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 8.50 AMA PRA Category 1 Credit™
  • 8.50 Attendance
Course opens: 
05/01/2026
Course expires: 
12/31/2026
Event starts: 
05/01/2026 - 8:00am CDT
Event ends: 
05/03/2026 - 4:00pm CDT
Rating: 
0

AAISG 2026 Annual Meeting
May 1-3, 2026
Stone Mountain Lakeside Resort, Stone Mountain GA

Friday, May 1, 2026
Rotunda

7:30 pm – 8:20 pm     Betty Wray Lecture and Dinner I Novel forms of Epinephrine Delivery I Jay Lieberman, MD
8:20 pm – 8:30 pm     Q & A Session    

Saturday, May 2, 2026
CME Sessions held in Laurel Amphitheatre
Breaks held in the Stone Mountain Ballroom

8:15 am – 9:05 am     Food Allergy Update | Brian Vickery, MD   
9:05 am – 9:15 am     Q & A Session
9:15 am – 9:30 am     Fellow-In-Training Emory Presentation – Secondary Immune Deficiency Associated with B-Cell and Plasma Cell Depleting Therapy in Adults I Kelly Cronin, MD
9:30 am – 9:40 am     Q & A Session
9:40 am – 9:55 am     Fellow-In-Training Emory Presentation - Comparison of Airborne Particulate Concentrations from an Automated Real-Time Sensor with Traditional Rotarod Sampling and Manual Counting I Wendi Bao, MD
9:55 am – 10:05 am    Q & A Session
10:05 am – 10:30 am     Break
10:30 am – 11:20 am     2026 Billing and Coding I Vivek Rao, MD (Brought to you by the American College of Allergy, Asthma & Immunology)
11:20 am – 11:30 am     Q & A Session
11:30 am – 12:20 pm     IEI Practice Parameter Update I Cullen Dutmer, MD
12:20 pm – 12:30 pm     Q & A Session
12:30 pm – 12:50 pm    Business Meeting (All members encouraged to attend) (non-CME)
12:50 pm – 1:20 pm     Lunch (Lake/Woodland)
1:20 pm – 2:10 pm     Anaphylaxis Practice Parameter Update: Deep Dive | Jay Lieberman, MD
2:10 pm – 2:20 pm     Q & A Session

Sunday, May 3, 2026
CME Sessions held in Laurel Amphitheatre
Breaks held in the Stone Mountain Ballroom

8:15 am – 9:05 am     Integrating ENT and Allergy Approaches in Nasal Polyps |Oswaldo Henriquez, MD
9:05 am – 9:15 am     Q & A Session
9:15 am – 9:30 am     Fellow-In-Training MCG Presentation - Immunological Screening Practices Prior to the Initiation of Rituximab Therapy: A Single-Center Retrospective Study | Adam Prevot, MD
9:30 am – 9:40 am     Q & A Session
9:40 am – 9:55 am     Fellow-In-Training MCG Presentation - Implementation of Noninvasive Endotyping Modalities for Nonallergic Rhinitis in Pediatric Populations | Hye Yoon, MD
9:55 am – 10:05 am     Q & A Session
10:05 am – 10:15 am    Break
10:15 am – 11:05 am      Non-Allergic Rhinitis I Brent Griffin, MD
11:05 am – 11:15 am     Q & A Session
12:45 pm  Adjourn

Lakeside Resort at Stone Mountain
4021 Lakeview Drive
Stone Mountain, GA 30083
United States

All relevant financial relationships with ineligible companies have been mitigated.

Rodney Johnson, MD, Planner
Speaker: AstraZeneca

Jay Lieberman, MD, Speaker
Advisor: Aquestive
Advisor/Consultant: ARS, Theravia, Genentech, Kaleo
Researcher: DBV
Consultant: Amgen, Abbvie, Celldex

Brian Vickery, MD, Speaker
Consultant: Genentech, Novartis, Parexel, Revolo, Seismic, Stallergenes Greer
Researcher: Aravax, AstraZeneca, DBV, Genentech, Novartis, RAPT, Regeneron, Siolta
Advisor: Reacta, Sanofi
Stock: Moonlight

The following have no relevant financial relationships with ineligible companies to disclose:
 
Wendi Bao, MD, Speaker
Richard Bickel, MD, Planner, Program Chair
Kelly Cronin, MD, Speaker
Cullen Dutmer, MD, Speaker
Dean Firschein, MD, Speaker
Brent Griffin, MD, Speaker
Oswaldo Henriquez, MD, Speaker
Adam Prevot, MD, Speaker
Vivek Rao, MD, Speaker
Jennifer Shih, MD, Speaker
Hye Yoon, MD, Speaker

Available Credit

  • 8.50 AMA PRA Category 1 Credit™
  • 8.50 Attendance
Please login or create an account to take this course.